查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1578246

全球阿哌沙班市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Apixaban Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 129 Pages | 商品交期: 最快1-2個工作天內

價格

全球阿哌沙班市場需求預計將從2023年的173.6億美元達到近337.1億美元的市場規模，2024-2032年研究期間複合年成長率為7.65%。

阿哌沙班是一種抗凝血藥物，用於治療和預防非瓣膜性心房顫動患者的血栓和中風。阿哌沙班是一種血液稀釋劑，旨在防止髖關節或膝關節置換手術後形成血栓，可能導致肺部血栓（肺栓塞）。它用來代替華法林，因為它不需要血液檢查或飲食限制。阿哌沙班屬於 Xa 因子抑制劑類藥物。它的作用是阻止一種有助於血栓形成的天然物質。阿哌沙班以 Eliquis 名稱上市。它以片劑形式口服。最常見的副作用是出血和噁心。不建議在懷孕或哺乳期間服用阿哌沙班。對於患有輕度腎臟問題的人來說，使用似乎相對安全。 Eliquis 與華法林相比，與較少的藥物產生交互作用。

市場動態

阿哌沙班治療適應症的不斷增加，心房顫動、靜脈血栓栓塞和中風盛行率的增加，大大促進了市場的成長。此外，老年人口的增加和肥胖症盛行率的增加正在補充市場的發展。此外，全球醫療保健支出的激增以及政府和私人組織對醫療保健研究和開發的大量投資的增加是推動阿哌沙班市場的其他關鍵因素。此外，新興經濟體的潛力不斷成長，以及醫療保健領域的技術進步和現代化程度不斷提高，將擴大阿哌沙班的市場。然而，阿哌沙班的副作用，例如服用太早會增加血栓事件和出血的風險，可能會限制其使用，從而阻礙市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對阿哌沙班全球市場的每個細分市場進行了包容性評估。阿哌沙班產業的成長和趨勢為本研究提供了整體方法。

市場區隔

阿哌沙班市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

依劑型分類

  • 膠囊
  • 藥片

按最終用戶

  • 醫院
  • 診所
  • 零售藥局
  • 網路藥局
  • 其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲阿哌沙班市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。阿哌沙班市場的主要參與者包括羅氏公司、Hikma Pharmaceuticals PLC、衛材有限公司、賽諾菲公司、一諾製藥有限公司、Mylan NV、百時美施貴寶公司、雅培實驗室、河北常山生化製藥有限公司、南京健友生化製藥有限公司、Aspen Holdings、Fresenius Kabi AG、輝瑞公司等。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：APIXABAN - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按劑型分類的市場吸引力分析
    • 最終用戶的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球 APIXABAN 市場分析：按劑型

  • 按劑型概述
  • 歷史和預測數據
  • 按劑型分析
  • 膠囊
  • 藥片

第 6 章：全球 APIXABAN 市場分析：依最終使用者分類

  • 最終用戶概述
  • 歷史和預測數據
  • 最終用戶分析
  • 醫院
  • 診所
  • 零售藥局
  • 網路藥局
  • 其他

第 7 章：全球 APIXABAN 市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 8 章：APIXABAN 公司的競爭格局

  • 阿哌沙班市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 9 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • F. Hoffmann-La Roche Ltd
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Hikma Pharmaceuticals PLC
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Eisai Co. Ltd
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Sanofi SA
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Yino Pharma Limited
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Mylan NV
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bristol Myers Squibb Company
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Abbott Laboratories
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Aspen Holdings
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Fresenius Kabi AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Pfizer Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • 其他
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR11216577

The global demand for Apixaban Market is presumed to reach the market size of nearly USD 33.71 Billion by 2032 from USD 17.36 Billion in 2023 with a CAGR of 7.65% under the study period 2024-2032.

Apixaban is an anticoagulant drug used to treat and prevent blood clots and strokes in people with nonvalvular atrial fibrillation. Apixaban is a blood thinner that is intended to prevent blood clots from forming following hip or knee replacement surgery, which can lead to lungs blood clots (pulmonary embolism). It's used instead of warfarin because it doesn't require blood tests or dietary restrictions. Apixaban belongs to the factor Xa inhibitors class of drugs. It works by stopping a natural substance that assist in the formation of blood clots. Apixaban is marketed under the name Eliquis. It is taken orally in the form of tablets. The most common side effects are bleeding and nausea. It is not recommended to take apixaban while pregnant or breastfeeding. In people with mild renal issues, it appears to be relatively safe to use. Eliquis interacts with fewer medications than warfarin.

MARKET DYNAMICS

Rising therapeutic indications for apixaban, an increase in the prevalence of atrial fibrillation, venous thromboembolism, and stroke are substantially contributing to the market growth. Furthermore, an increase in the geriatric population, an increase in the prevalence of obesity are supplementing market development. Additionally, a rising surge in healthcare expenditures worldwide and increasing government and private organizations investing significantly in healthcare research and development are other key factors driving the apixaban market. Moreover, rising potential in emerging economies, and increasing technological advancements and modernization in the healthcare sector, will expand the market for apixaban. However, apixaban's side effects, such as an increased risk of thrombotic events and bleeding if taken too soon, are likely to limit its use, thereby hampering the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Apixaban. The growth and trends of Apixaban industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Apixaban market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dosage Form

  • Capsule
  • Tablet

By End-User

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Apixaban market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Apixaban market include F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Eisai Co. Ltd, Sanofi S.A., Yino Pharma Limited, Mylan N.V., Bristol Myers Squibb Company, Abbott Laboratories, Hebei Changshan Biochemical Pharmaceutical Co. Ltd, Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd., Aspen Holdings, Fresenius Kabi AG, Pfizer Inc., Others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. APIXABAN - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Dosage Form
    • 3.7.2 Market Attractiveness Analysis By End-User
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL APIXABAN MARKET ANALYSIS BY DOSAGE FORM

  • 5.1. Overview By Dosage Form
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Dosage Form
  • 5.4. Capsule Historic and Forecast Sales By Regions
  • 5.5. Tablet Historic and Forecast Sales By Regions

6. GLOBAL APIXABAN MARKET ANALYSIS BY END-USER

  • 6.1. Overview By End-User
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By End-User
  • 6.4. Hospitals Historic and Forecast Sales By Regions
  • 6.5. Clinics Historic and Forecast Sales By Regions
  • 6.6. Retail Pharmacies Historic and Forecast Sales By Regions
  • 6.7. Online Pharmacies Historic and Forecast Sales By Regions
  • 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL APIXABAN MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE APIXABAN COMPANIES

  • 8.1. Apixaban Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF APIXABAN INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. F. Hoffmann-La Roche Ltd
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Hikma Pharmaceuticals PLC
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Eisai Co. Ltd
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. Sanofi S.A.
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. Yino Pharma Limited
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. Mylan N.V.
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. Bristol Myers Squibb Company
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. Abbott Laboratories
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. Hebei Changshan Biochemical Pharmaceutical Co. Ltd
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments
  • 9.12. Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
    • 9.12.1 Company Overview
    • 9.12.2 Company Revenue
    • 9.12.3 Products
    • 9.12.4 Recent Developments
  • 9.13. Aspen Holdings
    • 9.13.1 Company Overview
    • 9.13.2 Company Revenue
    • 9.13.3 Products
    • 9.13.4 Recent Developments
  • 9.14. Fresenius Kabi AG
    • 9.14.1 Company Overview
    • 9.14.2 Company Revenue
    • 9.14.3 Products
    • 9.14.4 Recent Developments
  • 9.15. Pfizer Inc.
    • 9.15.1 Company Overview
    • 9.15.2 Company Revenue
    • 9.15.3 Products
    • 9.15.4 Recent Developments
  • 9.16. Others
    • 9.16.1 Company Overview
    • 9.16.2 Company Revenue
    • 9.16.3 Products
    • 9.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Dosage Form (USD MN)
  • Capsule Market Sales By Geography (USD MN)
  • Tablet Market Sales By Geography (USD MN)
  • Analysis By End-User (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Apixaban Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Apixaban Report
  • Market Research Process
  • Market Research Methodology
  • Global Apixaban Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Dosage Form
  • Market Attractiveness Analysis By End-User
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Dosage Form (USD MN)
  • Capsule Market Sales By Geography (USD MN)
  • Tablet Market Sales By Geography (USD MN)
  • Global Market Analysis By End-User (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.